The ALGONQUIN Study: A Phase 1/2 Multi-Center, Dose Escalation Study to Determine the RP2D, Safety and Efficacy of GSK2857916 in Combination with Pomalidomide and Low Dose Dexamethasone in Subjects with RRMM



- Pom eligible patients
- ≥ 2 prior lines of treatment and Len and PI exposed (Cohort 1a)
- 7 patients enrolled at 2.5 mg/kg dose
- 1 unevaluable for DLT assessment
- 7 evaluable for response after at least one cycle

Determination of MTD and Recommended Phase 2 Dose (RP2D)

		POM mg Days 1-21	DEX mg Days 1.8.15.22	GSK2857916 mg/kg
Phase I	Cohort -1	4	40 mg QD ≤ 75 years of age	1.92
	Cohort 1a	4	20 mg QD > 75 years of age	2.5
	Cohort 1b			2.5 split
	Cohort 2			3.4 split

→ 35 patients at the RP2D to determine ORR

Clinicaltrials.gov identifier: NCT03715478

Algonquin Study: Demographics and Baseline Characteristics of patients enrolled at 2.5 mg/kg dose

Characteristic	2.5 mg/kg cohort (N=7)
Age (years), median (min-max)	54 (49-68)
Females/males, %	29/71
Median prior lines, min-max	3 (2-5)
ASCT	6 (86)
IMiDs Lenalidomide Pomalidomide **Refractory to IMiD**	**7 (100)** 7 (100) 0 (0) **6 (86)**
Proteasome inhibitor Bortezomib Carfilzomib **Refractory to PI**	**100 (100)** 7 (100) 3 (43) **5 (71)**
Daratumumab **Refractory to daratumumab**	**1 (14)** **1 (14)**
Refractory to IMiD/PI	**4 (57)**
Refractory to IMiD/PI and prior daratumumab	**1 (14)**
Cytogenetics risk, n (%)* High risk Missing	 4 (57) 1 (14)

*Patients with any of the following genetic abnormalities were considered high risk: t(4;14); del17, t(14:16), t(14:20) or gain 1q.

ASCT, autologous stem cell transplant; IMiD, immunomodulator; PI, proteasome inhibitor

Algonquin Study 2.5mg/kg cohort: AEs Occurring in ≥ 30% Regardless of Relationship

n (%)	N=7	
	Any grade	≥Grade 3*
Any event	7 (100)	7 (100)
Thrombocytopenia	6 (86)	2 (29)
Neutropenia	5 (71)	1 (14)
Eye disorder	7 (100)	7 (100)
Glaucoma*	5 (71)	1 (14)
Fatigue	4 (57)	1 (14)
MSK and connective tissue disorder	5 (71)	0 (0)
Insomnia	4 (57)	0 (0)
Rash	3 (43)	0 (0)
Fever	3 (43)	0 (0)

- One DLT: grade 3 corneal toxicity
- With the exception of pneumonitis, no unexpected toxicity
- Most frequent ≥Grade 3 AEs were eye disorder (100%) and thrombocytopenia (29%)
- No AEs leading to study treatment discontinuation
- No Grade 4/5 events were reported
- No SAEs

data cut August 26, 2019

AE, adverse event; SAE, serious AE; MSK, musculoskeletal

Algonquin Study 2.5 mg/kg cohort: Maximum response and Duration of Study Treatment

ORR = 7/7 (100%)
- **1 sCR, 6 VGPR**



data cut August 26, 2019

CR, complete response; ORR, overall response rate; PR, partial response; sCR, stringent complete response; VGPR, very good partial response